• Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
Quantisnow Logo
  • Live Feeds
    • Press Releases
    • Insider Trading
    • FDA Approvals
    • Analyst Ratings
    • Insider Trading
    • SEC filings
    • Market insights
  • Analyst Ratings
  • Alerts
  • Subscriptions
  • AI SuperconnectorNEW
  • Settings
  • RSS Feeds
PublishGo to AppAI Superconnector
    Quantisnow Logo

    © 2025 quantisnow.com
    Democratizing insights since 2022

    Services
    Live news feedsRSS FeedsAlertsPublish with Us
    Company
    AboutQuantisnow PlusContactJobsAI superconnector for talent & startupsNEW
    Legal
    Terms of usePrivacy policyCookie policy

    Amendment: SEC Form SCHEDULE 13G/A filed by Theratechnologies Inc.

    8/5/25 3:08:52 PM ET
    $THTX
    Biotechnology: Pharmaceutical Preparations
    Health Care
    Get the next $THTX alert in real time by email



    SECURITIES AND EXCHANGE COMMISSION
    Washington, D.C. 20549


    SCHEDULE 13G


    UNDER THE SECURITIES EXCHANGE ACT OF 1934
    (Amendment No. 3)


    Theratechnologies Inc.

    (Name of Issuer)


    Common Shares

    (Title of Class of Securities)


    88338H704

    (CUSIP Number)


    06/30/2025

    (Date of Event Which Requires Filing of this Statement)


    Check the appropriate box to designate the rule pursuant to which this Schedule is filed:
    Checkbox checked   Rule 13d-1(b)
    Checkbox not checked   Rule 13d-1(c)
    Checkbox not checked   Rule 13d-1(d)






    SCHEDULE 13G

    CUSIP No.
    88338H704


    1Names of Reporting Persons

    Morgan Stanley
    2Check the appropriate box if a member of a Group (see instructions)

    Checkbox not checked  (a)
    Checkbox not checked  (b)
    3Sec Use Only
    4Citizenship or Place of Organization

    DELAWARE
    Number of Shares Beneficially Owned by Each Reporting Person With:
    5Sole Voting Power

    0.00
    6Shared Voting Power

    852,939.00
    7Sole Dispositive Power

    0.00
    8Shared Dispositive Power

    858,614.00
    9Aggregate Amount Beneficially Owned by Each Reporting Person

    858,614.00
    10Check box if the aggregate amount in row (9) excludes certain shares (See Instructions)

    Checkbox not checked
    11Percent of class represented by amount in row (9)

    1.9 %
    12Type of Reporting Person (See Instructions)

    HC, CO

    Comment for Type of Reporting Person:  As of the date hereof, Morgan Stanley has ceased to be the beneficial owner of more than five percent of the class of securities.


    SCHEDULE 13G

    Item 1. 
    (a)Name of issuer:

    Theratechnologies Inc.
    (b)Address of issuer's principal executive offices:

    2015 PEEL STREET, 5TH FLOOR, MONTREAL, A8, H3A 1T8
    Item 2. 
    (a)Name of person filing:

    Morgan Stanley
    (b)Address or principal business office or, if none, residence:

    1585 Broadway, New York, NY 10036
    (c)Citizenship:

    Delaware
    (d)Title of class of securities:

    Common Shares
    (e)CUSIP No.:

    88338H704
    Item 3.If this statement is filed pursuant to §§ 240.13d-1(b) or 240.13d-2(b) or (c), check whether the person filing is a:
    (a)Checkbox not checked   Broker or dealer registered under section 15 of the Act (15 U.S.C. 78o);
    (b)Checkbox not checked   Bank as defined in section 3(a)(6) of the Act (15 U.S.C. 78c);
    (c)Checkbox not checked   Insurance company as defined in section 3(a)(19) of the Act (15 U.S.C. 78c);
    (d)Checkbox not checked   Investment company registered under section 8 of the Investment Company Act of 1940 (15 U.S.C. 80a-8);
    (e)Checkbox not checked   An investment adviser in accordance with § 240.13d-1(b)(1)(ii)(E);
    (f)Checkbox not checked   An employee benefit plan or endowment fund in accordance with § 240.13d-1(b)(1)(ii)(F);
    (g)Checkbox checked   A parent holding company or control person in accordance with § 240.13d-1(b)(1)(ii)(G);
    (h)Checkbox not checked   A savings associations as defined in Section 3(b) of the Federal Deposit Insurance Act (12 U.S.C. 1813);
    (i)Checkbox not checked   A church plan that is excluded from the definition of an investment company under section 3(c)(14) of the Investment Company Act of 1940 (15 U.S.C. 80a-3);
    (j)Checkbox not checked   A non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J). If filing as a non-U.S. institution in accordance with § 240.13d-1(b)(1)(ii)(J),
           please specify the type of institution:
    (k)Checkbox not checked   Group, in accordance with Rule 240.13d-1(b)(1)(ii)(K).
     
    Item 4.Ownership
    (a)Amount beneficially owned:

    See the response(s) to Item 9 on the attached cover page(s).
    (b)Percent of class:

    1.9  %
    (c)Number of shares as to which the person has:
     (i) Sole power to vote or to direct the vote:

    See the response(s) to Item 5 on the attached cover page(s).

     (ii) Shared power to vote or to direct the vote:

    See the response(s) to Item 6 on the attached cover page(s).

     (iii) Sole power to dispose or to direct the disposition of:

    See the response(s) to Item 7 on the attached cover page(s).

     (iv) Shared power to dispose or to direct the disposition of:

    See the response(s) to Item 8 on the attached cover page(s).

    Item 5.Ownership of 5 Percent or Less of a Class.
     
    Checkbox checked    Ownership of 5 percent or less of a class
    Item 6.Ownership of more than 5 Percent on Behalf of Another Person.
     
    Not Applicable
    Item 7.Identification and Classification of the Subsidiary Which Acquired the Security Being Reported on by the Parent Holding Company or Control Person.
     
    Not Applicable
    Item 8.Identification and Classification of Members of the Group.
     
    Not Applicable
    Item 9.Notice of Dissolution of Group.
     
    Not Applicable

    Item 10.Certifications:
     
    By signing below I certify that, to the best of my knowledge and belief, the securities referred to above were acquired and are held in the ordinary course of business and were not acquired and are not held for the purpose of or with the effect of changing or influencing the control of the issuer of the securities and were not acquired and are not held in connection with or as a participant in any transaction having that purpose or effect, other than activities solely in connection with a nomination under ?? 240.14a-11. * In Accordance with the Securities and Exchange Commission Release No. 34-39538 (January 12, 1998) (the "Release"), this filing reflects the securities beneficially owned, or that may be deemed to be beneficially owned, by certain operating units (collectively, the "MS Reporting Units") of Morgan Stanley and its subsidiaries and affiliates (collectively, "MS"). This filing does not reflect securities, if any, beneficially owned by any operating units of MS whose ownership of securities is disaggregated from that of the MS Reporting Units in accordance with the Release.

        SIGNATURE 
     
    After reasonable inquiry and to the best of my knowledge and belief, I certify that the information set forth in this statement is true, complete and correct.

     
    Morgan Stanley
     
    Signature:Christopher O'Hara
    Name/Title:Authorized Signatory, Morgan Stanley
    Date:08/05/2025
    Get the next $THTX alert in real time by email

    Crush Q3 2025 with the Best AI Superconnector

    Stay ahead of the competition with Standout.work - your AI-powered talent-to-startup matching platform.

    AI-Powered Inbox
    Context-aware email replies
    Strategic Decision Support
    Get Started with Standout.work

    Recent Analyst Ratings for
    $THTX

    DatePrice TargetRatingAnalyst
    11/17/2022$9.00Overweight
    Cantor Fitzgerald
    7/29/2021$8.00 → $3.00Buy → Hold
    Canaccord Genuity
    More analyst ratings

    $THTX
    Press Releases

    Fastest customizable press release news feed in the world

    View All

    Theratechnologies Announces Filing of Special Meeting Materials and Receipt of Interim Order in Relation to its Acquisition by CB Biotechnology, an Affiliate of Future Pak

    Shareholders stand to receive a significant and attractive cash premium, as the purchase price of US$3.01, with a contingent value right for potential additional aggregate payments of up to US$1.19 per share, represents a compelling premium of 216% to the closing price on the Nasdaq on April 10, 2025, the date prior to the announcement of Future Pak's initial non-binding proposal.Board unanimously recommends shareholders vote "FOR" the Arrangement.Shareholders are encouraged to review the circular carefully and submit their proxies in advance of the proxy voting deadline of 10:00 a.m. (Eastern time) on September 10, 2025.Visit www.theratech.com for more information.Questions or require votin

    8/18/25 7:30:00 AM ET
    $THTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Theratechnologies Reports Financial Results for the Second Quarter 2025

    Q2 2025 total revenue of $17.7 million, and $36.8 million for the first six months of Fiscal 2025Positive Adjusted EBITDA1 for the fifth straight quarterSubsequent to quarter end, Theratechnologies entered into a definitive agreement to be acquired by an affiliate of Future Pak MONTREAL, July 09, 2025 (GLOBE NEWSWIRE) -- Theratechnologies Inc. ("Theratechnologies" or the "Company") (TSX:TH) (NASDAQ:THTX), a commercial-stage biopharmaceutical company, today reported business highlights and financial results for the second quarter 2025, ended May 31, 2025. All figures are in U.S. dollars unless otherwise stated. "Demand for EGRIFTA SV® remains very strong and we are witnessing

    7/9/25 7:30:00 AM ET
    $THTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Theratechnologies to Announce Second Quarter 2025 Financial Results

    MONTREAL, July 03, 2025 (GLOBE NEWSWIRE) -- Theratechnologies Inc. ("Theratechnologies" or the "Company") (TSX:TH) (NASDAQ:THTX), a commercial-stage biopharmaceutical company, today announced the Company will report financial results for its second quarter 2025 ended May 31 on Wednesday, July 9, 2025. Given the announcement of July 2, 2025, concerning the acquisition of the Company, a conference call will not be held. About Theratechnologies Theratechnologies (TSX:TH) (NASDAQ:THTX) is a specialty biopharmaceutical company focused on the commercialization of innovative therapies that have the potential to redefine standards of care. Further information about Theratechnologies is availabl

    7/3/25 5:30:00 PM ET
    $THTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $THTX
    Analyst Ratings

    Analyst ratings in real time. Analyst ratings have a very high impact on the underlying stock. See them live in this feed.

    View All

    Cantor Fitzgerald initiated coverage on Theratechnologies with a new price target

    Cantor Fitzgerald initiated coverage of Theratechnologies with a rating of Overweight and set a new price target of $9.00

    11/17/22 7:27:25 AM ET
    $THTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Theratechnologies downgraded by Canaccord Genuity with a new price target

    Canaccord Genuity downgraded Theratechnologies from Buy to Hold and set a new price target of $3.00 from $8.00 previously

    7/29/21 9:53:58 AM ET
    $THTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Canaccord Genuity reiterated coverage on Theratechnologies with a new price target

    Canaccord Genuity reiterated coverage of Theratechnologies with a rating of Buy and set a new price target of $8.00 from $7.00 previously

    4/19/21 9:31:33 AM ET
    $THTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $THTX
    SEC Filings

    View All

    SEC Form 6-K filed by Theratechnologies Inc.

    6-K - Theratechnologies Inc. (0001512717) (Filer)

    8/18/25 8:15:52 AM ET
    $THTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form 6-K filed by Theratechnologies Inc.

    6-K - Theratechnologies Inc. (0001512717) (Filer)

    8/18/25 7:52:04 AM ET
    $THTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Amendment: SEC Form SCHEDULE 13G/A filed by Theratechnologies Inc.

    SCHEDULE 13G/A - Theratechnologies Inc. (0001512717) (Subject)

    8/5/25 3:08:52 PM ET
    $THTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $THTX
    Leadership Updates

    Live Leadership Updates

    View All

    Theratechnologies Appoints Elina Tea to its Board of Directors

    MONTREAL, April 05, 2024 (GLOBE NEWSWIRE) -- Theratechnologies Inc. ("Theratechnologies" or the "Company") (TSX:TH) (NASDAQ:THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today announced the appointment of Elina Tea, Chief Financial Officer at GLS North America, to its Board of Directors and as a member of the Company's Audit Committee. Ms. Tea will be Investissement Québec's designee pursuant to its investor rights agreement with the Company. "Elina Tea's extensive experience in finance, corporate strategy, and investor relations makes her a valuable addition to our Board of Directors," said Dawn Svoronos, Chair of the Board o

    4/5/24 11:00:00 AM ET
    $THTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Theratechnologies Appoints Jordan Zwick to its Board of Directors

    MONTREAL, March 21, 2024 (GLOBE NEWSWIRE) -- Theratechnologies Inc. ("Theratechnologies" or the "Company") (TSX:TH) (NASDAQ:THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today announced the appointment of Jordan Zwick, Chief Business Officer at Mirador Therapeutics Inc., to its Board of Directors and as a member of the Company's Audit Committee. "We welcome Jordan Zwick to the Board as an important addition to our esteemed group of advisors," said Dawn Svoronos, Chair of the Board of Directors at Theratechnologies. "With his extensive experience in the U.S. biotech and pharmaceutical industry, coupled with expertise in global

    3/21/24 8:00:00 PM ET
    $THTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Theratechnologies Announces the Resignation of One of Its Directors, Mr. Alain Trudeau

    MONTREAL, Feb. 29, 2024 (GLOBE NEWSWIRE) -- Theratechnologies Inc. ("Theratechnologies" or the "Company") (TSX:TH) (NASDAQ:THTX), a biopharmaceutical company focused on the development and commercialization of innovative therapies, today announced that Mr. Alain Trudeau has resigned from the Board of Directors of Theratechnologies and as a member of its Audit Committee, effective immediately. "I want to thank Alain for his contributions to Theratechnologies as a director since joining the Company in October 2020 and for completing the annual review for the 2023 fiscal year", said Dawn Svoronos, Chair of the Board at Theratechnologies. "Alain was the current Chair of the Audit Committee

    2/29/24 4:34:00 PM ET
    $THTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $THTX
    Financials

    Live finance-specific insights

    View All

    Theratechnologies Reports Financial Results for the Second Quarter 2025

    Q2 2025 total revenue of $17.7 million, and $36.8 million for the first six months of Fiscal 2025Positive Adjusted EBITDA1 for the fifth straight quarterSubsequent to quarter end, Theratechnologies entered into a definitive agreement to be acquired by an affiliate of Future Pak MONTREAL, July 09, 2025 (GLOBE NEWSWIRE) -- Theratechnologies Inc. ("Theratechnologies" or the "Company") (TSX:TH) (NASDAQ:THTX), a commercial-stage biopharmaceutical company, today reported business highlights and financial results for the second quarter 2025, ended May 31, 2025. All figures are in U.S. dollars unless otherwise stated. "Demand for EGRIFTA SV® remains very strong and we are witnessing

    7/9/25 7:30:00 AM ET
    $THTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Theratechnologies to Announce Second Quarter 2025 Financial Results

    MONTREAL, July 03, 2025 (GLOBE NEWSWIRE) -- Theratechnologies Inc. ("Theratechnologies" or the "Company") (TSX:TH) (NASDAQ:THTX), a commercial-stage biopharmaceutical company, today announced the Company will report financial results for its second quarter 2025 ended May 31 on Wednesday, July 9, 2025. Given the announcement of July 2, 2025, concerning the acquisition of the Company, a conference call will not be held. About Theratechnologies Theratechnologies (TSX:TH) (NASDAQ:THTX) is a specialty biopharmaceutical company focused on the commercialization of innovative therapies that have the potential to redefine standards of care. Further information about Theratechnologies is availabl

    7/3/25 5:30:00 PM ET
    $THTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    Theratechnologies enters into Definitive Agreement to be Acquired by CB Biotechnology, an Affiliate of Future Pak

    Offer of US$3.01 in cash plus one contingent value right for potential additional aggregate payments of up to US$1.19 per shareUpfront and total potential cash consideration represent respectively a 126% and 216% premium to Nasdaq closing price on date prior to announcement of Future Pak's initial non-binding proposalTransaction with Future Pak represents culmination of sale process whereby Theratechnologies solicited interest from a number of potential counterpartiesBoard unanimously recommends that shareholders approve the transaction MONTREAL, July 02, 2025 (GLOBE NEWSWIRE) -- Theratechnologies Inc. ("Theratechnologies" or the "Company") (TSX:TH) (NASDAQ:THTX), a commercial-stage bio

    7/2/25 10:11:00 PM ET
    $THTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    $THTX
    Large Ownership Changes

    This live feed shows all institutional transactions in real time.

    View All

    SEC Form SC 13G filed by Theratechnologies Inc.

    SC 13G - Theratechnologies Inc. (0001512717) (Subject)

    2/14/24 4:51:41 PM ET
    $THTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13G/A filed by Theratechnologies Inc. (Amendment)

    SC 13G/A - Theratechnologies Inc. (0001512717) (Subject)

    2/7/24 6:55:18 PM ET
    $THTX
    Biotechnology: Pharmaceutical Preparations
    Health Care

    SEC Form SC 13D filed by Theratechnologies Inc.

    SC 13D - Theratechnologies Inc. (0001512717) (Subject)

    11/28/23 4:52:43 PM ET
    $THTX
    Biotechnology: Pharmaceutical Preparations
    Health Care